|NASDAQ: FIXX||Healthcare / Biotechnology / USA|
|1.10||-0.0050||-0.45%||Vol 18.13K||1Y Perf -50.45%|
|Jun 8th, 2023 11:26 DELAYED|
|- -%||- -|
|Target Price||8.75||Analyst Rating||Moderate Buy 1.67|
|Potential %||695.53||Finscreener Ranking||★★★★★ 63.70|
|Insiders Trans % 3/6/12 mo.||-/-/-100||Value Ranking||★★★★ 57.06|
|Insiders Value % 3/6/12 mo.||-/-/-100||Growth Ranking||★★★★★ 67.84|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-100||Income Ranking||— -|
|Price Range Ratio 52W %||9.63||Earnings Rating||Strong Buy|
|Market Cap||63.29M||Earnings Date||15th May 2023|
Today's Price Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|-80 427 600.00|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.55|
|EPS Growth Next 5 Years %||37.10|
|Avg. Weekly Volume||63.60K|
|Avg. Monthly Volume||83.73K|
|Avg. Quarterly Volume||143.40K|
Homology Medicines Inc. (NASDAQ: FIXX) stock closed at 1.1 per share at the end of the most recent trading day (a 5.77% change compared to the prior day closing price) with a volume of 91.02K shares and market capitalization of 63.28M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 206 people. Homology Medicines Inc. CEO is Arthur O. Tzianabos.
The one-year performance of Homology Medicines Inc. stock is -50.45%, while year-to-date (YTD) performance is -12.7%. FIXX stock has a five-year performance of -94.68%. Its 52-week range is between 0.86 and 3.3, which gives FIXX stock a 52-week price range ratio of 9.63%
Homology Medicines Inc. currently has a PE ratio of -15.80, a price-to-book (PB) ratio of 0.43, a price-to-sale (PS) ratio of 39.42, a price to cashflow ratio of 57.40, a PEG ratio of 2.32, a ROA of -1.74%, a ROC of -2.39% and a ROE of -2.11%. The company’s profit margin is -28.78%, its EBITDA margin is -4 031.90%, and its revenue ttm is $2.41 Million , which makes it $0.04 revenue per share.
Of the last four earnings reports from Homology Medicines Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.55 for the next earnings report. Homology Medicines Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Homology Medicines Inc. is Moderate Buy (1.67), with a target price of $8.75, which is +695.53% compared to the current price. The earnings rating for Homology Medicines Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Homology Medicines Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Homology Medicines Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 19.41, ATR14 : 0.07, CCI20 : 125.79, Chaikin Money Flow : 0.11, MACD : 0.00, Money Flow Index : 51.89, ROC : 3.77, RSI : 61.60, STOCH (14,3) : 93.75, STOCH RSI : 1.00, UO : 51.95, Williams %R : -6.25), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Homology Medicines Inc. in the last 12-months were: Albert Seymour (Option Excercise at a value of $0), Albert Seymour (Sold 7 240 shares of value $10 067 ), Alloway Paul (Sold 10 965 shares of value $15 899 ), Arthur O. Tzianabos (Option Excercise at a value of $0), Arthur O. Tzianabos (Sold 21 232 shares of value $29 523 ), Michael Blum (Option Excercise at a value of $0), Michael Blum (Sold 2 454 shares of value $3 412 ), Paul Alloway (Option Excercise at a value of $0), Paul Alloway (Sold 14 055 shares of value $20 159 ), W. Bradford Smith (Option Excercise at a value of $0), W. Bradford Smith (Sold 7 458 shares of value $10 376 )
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Moderate Buy||Moderate Buy||Strong Buy|
Homology Medicines Inc is an US based is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
CEO: Arthur O. Tzianabos
Telephone: +1 781 301-7277
Address: One Patriots Park, Bedford 01730, MA, US
Number of employees: 206
Tue, 16 May 2023 01:45 GMT Homology Medicines (FIXX) Gets a Hold from RBC Capital- TipRanks. All rights reserved.
Wed, 22 Mar 2023 01:32 GMT Analysts Are Bullish on Top Healthcare Stocks: Homology Medicines (FIXX), Mereo Biopharma Group Plc (MREO)- TipRanks. All rights reserved.
Tue, 14 Mar 2023 02:05 GMT Homology Medicines (FIXX) Gets a Hold from Stifel Nicolaus- TipRanks. All rights reserved.
Mon, 13 Mar 2023 05:55 GMT Homology Medicines (FIXX) Gets a Buy from Robert W. Baird- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.